Ensysce’s TAAP™ prodrug technology is a game changer in the abuse deterrent field
TAAP™ AND MPAR™ PLATFORMS
Ensysce Biosciences' proprietary abuse-resistant prodrug technology – the TAAP™ platform - is designed to improve the care of patients while reducing the human and economic costs associated with prescription drug abuse. Our TAAP™ technology has been applied to a family of opioid and attention deficit disorder products.
Several abuse-deterrent opioid products are currently marketed or in late-stage clinical development, but they fall short of being fully resistant to abuse.
Our prodrugs are chemically stable molecules that are activated only when administered orally.
Since the activating enzymes are not present in the blood or saliva, there is no opportunity for activation if injected, chewed or snorted.
In addition, Ensysce's Multi-Pill Abuse Resistant - MPAR™ - technology is designed to provide another layer of protection to our TAAP™ products. It is unique to the industry and designed not only to overcome abuse but to save lives by preventing overdose.